Wealthcome
Seed Round in 2023
Wealthcome is a technology company specializing in wealth management solutions. It has developed a comprehensive platform that enables users to monitor, analyze, and optimize their assets, including bank accounts, investments, and real estate. The platform offers tools for expense tracking, fee optimization, and investment performance analysis, empowering clients to take control of their financial portfolios.
Nurea is a company that focuses on providing decision-making support solutions for healthcare professionals, particularly vascular surgeons. It specializes in the development of medical imaging software aimed at the diagnosis of vascular diseases. Nurea's platform automates the analysis of medical images, offering accurate quantitative assessments and decision indicators that assist in managing patient groups during both pre and post-operative monitoring. By streamlining the workflow associated with full-body scan analysis, Nurea enables surgeons to simplify their decision-making processes and improve patient outcomes in the context of cardiovascular diseases.
VISME rehabilitation service. Medical service providing new opportunities for rehabilitation. They work at the junction of neurobiology and machine learning. They use computer vision technologies to automatize the methods of rehabilitation.
Novaled AG is a leading technology provider specializing in organic light-emitting diode (OLED) technologies. Founded in March 2003 and headquartered in Dresden, Germany, the company develops high-efficiency, long-lifetime OLED structures, leveraging its expertise in synthetic and analytical chemistry. Novaled offers comprehensive solutions for the organic electronic markets, including customized OLED products and services used in various applications, such as televisions and mobile phones. The company has established long-term partnerships with major players in the OLED industry and holds a robust intellectual property portfolio, with over 500 patents granted or pending. Additionally, Novaled has branch offices in Asia to support its global operations.
Ascendis Pharma
Series A in 2007
Ascendis Pharma A/S is a biopharmaceutical company based in Hellerup, Denmark, focused on developing prodrug therapies to address unmet medical needs. Leveraging its innovative TransCon technology platform, the company aims to create superior prodrugs across various drug classes, including proteins, peptides, and small molecules. Its pipeline includes TransCon growth hormone, which has completed Phase III clinical trials for treating growth hormone deficiency in children, and TransCon parathyroid hormone, currently in Phase II trials for hypoparathyroidism. Additionally, TransCon CNP is in Phase II development for achondroplasia. Ascendis Pharma also explores preclinical studies in oncology and employs strategic collaborations to enhance its product development, aiming for systemic and localized drug delivery. The company primarily operates in North America, with additional activities in Europe and China.
Novaled AG is a leading technology provider specializing in organic light-emitting diode (OLED) technologies. Founded in March 2003 and headquartered in Dresden, Germany, the company develops high-efficiency, long-lifetime OLED structures, leveraging its expertise in synthetic and analytical chemistry. Novaled offers comprehensive solutions for the organic electronic markets, including customized OLED products and services used in various applications, such as televisions and mobile phones. The company has established long-term partnerships with major players in the OLED industry and holds a robust intellectual property portfolio, with over 500 patents granted or pending. Additionally, Novaled has branch offices in Asia to support its global operations.
NXN Software
Series C in 2001
NXN Software is supplier of Digital Asset and Production Management solutions for the computer graphics and digital entertainment industries.